2-(3,5-bis(trifluoromethyl)phenyl)-2-((4-(2-fluorophenyl)pyridin-3-yl)methylamino)acetic acid methyl ester | 1491169-19-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-(3,5-bis(trifluoromethyl)phenyl)-2-((4-(2-fluorophenyl)pyridin-3-yl)methylamino)acetic acid methyl ester
• 英文别名: methyl 2-(3,5-bis(trifluoromethyl)phenyl)-2-((4-(2-fluorophenyl)pyridin-3-yl)methylamino)acetate；Methyl 2-[3,5-bis(trifluoromethyl)phenyl]-2-[[4-(2-fluorophenyl)pyridin-3-yl]methylamino]acetate；methyl 2-[3,5-bis(trifluoromethyl)phenyl]-2-[[4-(2-fluorophenyl)pyridin-3-yl]methylamino]acetate
• CAS: 1491169-19-7
• 化学式: C₂₃H₁₇F₇N₂O₂
• 分子量: 486.389
• InChiKey: GEMHCOAHIKZOMD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  34
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  51.2
• 氢给体数：
  1
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  2-(3,5-bis(trifluoromethyl)phenyl)-2-((4-(2-fluorophenyl)pyridin-3-yl)methylamino)acetic acid methyl ester 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 以69%的产率得到2-(3,5-bis(trifluoromethyl)phenyl)-2-((4-(2-fluorophenyl)pyridin-3-yl)methylamino)acetic acid
  参考文献：
  名称：

  Design, synthesis and biological evaluation of a novel class of potent TGR5 agonists based on a 4-phenyl pyridine scaffold

  摘要：

  TGR5, a GPCR, is involved in energy and glucose homeostasis, and as such, is a target for the treatment of diabetes, obesity and other metabolic syndromes. A new class of TGR5 agonists based on a 4-phenyl pyridine scaffold was designed, synthesized and evaluated in vitro and in vivo. Extensive structure activity relationship studies are reported herein. The most potent compounds 15a, 18b and 18c showed comparable activity with the lead compound 2. 15a had the best potency in vitro but displayed an pharmacokinetic profile and was found to be ineffective during an oral glucose tolerance test in imprinting control region mice at a dose of 50 mg/kg. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.07.050
• 作为产物：
  描述：

  3,5-双(三氟甲基)苯基乙酸甲酯 在 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 、 三乙胺 作用下， 以 四氯化碳 、 乙腈 为溶剂， 反应 51.5h， 生成 2-(3,5-bis(trifluoromethyl)phenyl)-2-((4-(2-fluorophenyl)pyridin-3-yl)methylamino)acetic acid methyl ester
  参考文献：
  名称：

  TGR5激动剂3,4,5-三取代的4,5-二氢-1,2,4-恶二唑的设计，合成与结构-活性关系

  摘要：

  鉴于其在能量和葡萄糖稳态中的介导作用，G蛋白偶联胆汁酸受体1（TGR5）被认为是治疗2型糖尿病和其他代谢性疾病的潜在靶标。通过对已发表的TGR5激动剂的各种结构进行全面分析，建立了一个假设的基于配体的药效团模型，并基于新型3,4,5-三取代的4,5-二氢-1，2来开发了一类新型的强效TGR5激动剂。 ，4-恶二唑核是通过合理设计发现的。本文报道了三种不同的合成方法来构建4,5-二氢-1,2,4-恶二唑和广泛的结构-活性关系研究。化合物（R）-54 n，其结构是通过单晶X-射线衍射和量子化学固态TDDFT-ECD计算确定，显示出最好的效力，用EC 50为1.4的n值中号朝向hTGR5。它在体外的有利特性值得进一步研究。

  DOI：

  10.1002/cmdc.201300144

文献信息

• 五元唑类杂环化合物及其制备方法、药物组合 物和用途
  申请人：中国科学院上海药物研究所

  公开号：CN103864754B

  公开（公告）日：2016-12-21

  本发明涉及一类如下通式（I）所示的五元唑类杂环化合物、其制备方法、药物组合物及其在制备预防或治疗由TGR5介导的疾病的药物中的用途。
• Design, Synthesis, and Structure-Activity Relationships of 3,4,5-Trisubstituted 4,5-Dihydro-1,2,4-oxadiazoles as TGR5 Agonists
  作者：Junjie Zhu、Yangliang Ye、Mengmeng Ning、Attila Mándi、Ying Feng、Qingan Zou、Tibor Kurtán、Ying Leng、Jianhua Shen

  DOI：10.1002/cmdc.201300144

  日期：2013.7

  By thorough analysis of diverse structures of published TGR5 agonists, a hypothetical ligand‐based pharmacophore model was built, and a new class of potent TGR5 agonists, based on the novel 3,4,5‐trisubstituted 4,5‐dihydro‐1,2,4‐oxadiazole core, was discovered by rational design. Three distinct synthetic methods for constructing 4,5‐dihydro‐1,2,4‐oxadiazoles and extensive structure–activity relationship

  鉴于其在能量和葡萄糖稳态中的介导作用，G蛋白偶联胆汁酸受体1（TGR5）被认为是治疗2型糖尿病和其他代谢性疾病的潜在靶标。通过对已发表的TGR5激动剂的各种结构进行全面分析，建立了一个假设的基于配体的药效团模型，并基于新型3,4,5-三取代的4,5-二氢-1，2来开发了一类新型的强效TGR5激动剂。 ，4-恶二唑核是通过合理设计发现的。本文报道了三种不同的合成方法来构建4,5-二氢-1,2,4-恶二唑和广泛的结构-活性关系研究。化合物（R）-54 n，其结构是通过单晶X-射线衍射和量子化学固态TDDFT-ECD计算确定，显示出最好的效力，用EC 50为1.4的n值中号朝向hTGR5。它在体外的有利特性值得进一步研究。
• Design, synthesis and biological evaluation of a novel class of potent TGR5 agonists based on a 4-phenyl pyridine scaffold
  作者：Junjie Zhu、Mengmeng Ning、Cen Guo、Lina Zhang、Guoyu Pan、Ying Leng、Jianhua Shen

  DOI：10.1016/j.ejmech.2013.07.050

  日期：2013.11

  TGR5, a GPCR, is involved in energy and glucose homeostasis, and as such, is a target for the treatment of diabetes, obesity and other metabolic syndromes. A new class of TGR5 agonists based on a 4-phenyl pyridine scaffold was designed, synthesized and evaluated in vitro and in vivo. Extensive structure activity relationship studies are reported herein. The most potent compounds 15a, 18b and 18c showed comparable activity with the lead compound 2. 15a had the best potency in vitro but displayed an pharmacokinetic profile and was found to be ineffective during an oral glucose tolerance test in imprinting control region mice at a dose of 50 mg/kg. (C) 2013 Elsevier Masson SAS. All rights reserved.